Welcome to our dedicated page for Bright Minds Biosciences SEC filings (Ticker: DRUG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bright Minds Biosciences files as a foreign issuer, and its SEC reports document clinical-stage biotechnology operations, capital formation and public-company governance. Form 6-K reports include interim condensed consolidated financial statements, management's discussion and analysis, executive certifications, material-event releases and exhibits incorporated by reference into Form F-3 registration statements.
The filings cover capital-structure disclosures for common shares, shelf registrations, public offerings and equity distribution arrangements, as well as clinical and regulatory updates for the company's 5-HT receptor agonist pipeline, including BMB-101. They also record operating and financial results, material agreements and shareholder voting matters tied to development-stage CNS drug programs.
Bright Minds Biosciences Inc. reports that, on January 7, 2026, it mutually agreed with Piper Sandler & Co. and Cantor Fitzgerald & Co. to terminate their Equity Distribution Agreement dated August 25, 2025, effective the same day. This agreement had allowed the company to distribute equity through these firms, and its termination ends that arrangement.
The company also notes that this disclosure is incorporated by reference into its registration statements on Form F-3 with file numbers 333-284694 and 333-289851.
Bright Minds Biosciences Inc. has filed a preliminary prospectus supplement for a $100,000,000 public offering of common shares and, for certain large investors, pre-funded warrants to buy common shares. The pre-funded warrants are sold at the share price minus $0.001 and carry a token exercise price of $0.001 per share, are exercisable at any time, and include 4.99% or 9.99% ownership caps to limit post‑offering beneficial ownership.
The company has also granted underwriters a 30‑day option to purchase additional common shares. Net proceeds are expected to fund future clinical trials in absence epilepsy, developmental and epileptic encephalopathies, Prader‑Willi Syndrome, initiation of phase 1 trials for BMB‑105, earlier-stage research programs, and general corporate purposes. Bright Minds had 7,787,161 common shares outstanding as of the prospectus supplement date, with additional shares reserved under options, RSUs and warrants, so this financing may significantly dilute existing holders and increase share count over time.
Bright Minds Biosciences Inc. has filed a preliminary prospectus supplement for a $100,000,000 public offering of common shares and, for certain large investors, pre-funded warrants to buy common shares. The pre-funded warrants are sold at the share price minus $0.001 and carry a token exercise price of $0.001 per share, are exercisable at any time, and include 4.99% or 9.99% ownership caps to limit post‑offering beneficial ownership.
The company has also granted underwriters a 30‑day option to purchase additional common shares. Net proceeds are expected to fund future clinical trials in absence epilepsy, developmental and epileptic encephalopathies, Prader‑Willi Syndrome, initiation of phase 1 trials for BMB‑105, earlier-stage research programs, and general corporate purposes. Bright Minds had 7,787,161 common shares outstanding as of the prospectus supplement date, with additional shares reserved under options, RSUs and warrants, so this financing may significantly dilute existing holders and increase share count over time.
Bright Minds Biosciences reported positive topline Phase 2 results from its BREAKTHROUGH trial of BMB-101 in adults with drug‑resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The open-label study enrolled 24 patients and met its primary efficacy endpoints in both cohorts, showing robust seizure reductions with a favorable safety profile.
In the Absence cohort (n=11 efficacy‑evaluable), BMB‑101 achieved a 73.1% median reduction in absence seizures lasting at least 3 seconds and a 74.4% median reduction in total seizure time, with p = 0.012. In the DEE cohort (n=6), there was a 63.3% median reduction in major motor seizures, including Lennox‑Gastaut, Dravet, and Rett patients.
BMB‑101 was generally well tolerated, with most adverse events mild or moderate and no treatment‑related serious events. Patients with Absence Seizures also showed a 90% increase in REM sleep without increasing total sleep time. Based on these findings, Bright Minds has begun preparations for global registrational trials in Absence Seizures and DEE and plans to start a Prader‑Willi syndrome study in Q1 2026.
Bright Minds Biosciences reported positive topline Phase 2 results from its BREAKTHROUGH trial of BMB-101 in adults with drug‑resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The open-label study enrolled 24 patients and met its primary efficacy endpoints in both cohorts, showing robust seizure reductions with a favorable safety profile.
In the Absence cohort (n=11 efficacy‑evaluable), BMB‑101 achieved a 73.1% median reduction in absence seizures lasting at least 3 seconds and a 74.4% median reduction in total seizure time, with p = 0.012. In the DEE cohort (n=6), there was a 63.3% median reduction in major motor seizures, including Lennox‑Gastaut, Dravet, and Rett patients.
BMB‑101 was generally well tolerated, with most adverse events mild or moderate and no treatment‑related serious events. Patients with Absence Seizures also showed a 90% increase in REM sleep without increasing total sleep time. Based on these findings, Bright Minds has begun preparations for global registrational trials in Absence Seizures and DEE and plans to start a Prader‑Willi syndrome study in Q1 2026.
Bright Minds Biosciences Inc. filed a Form 6-K as a foreign private issuer for November 2025. The filing furnishes a news release dated November 17, 2025 as Exhibit 99.1. That news release is incorporated by reference into the company’s two existing Form F-3 shelf registration statements.
Bright Minds Biosciences Inc. filed an amended Form 6-K to update a prior submission for November 2025. The amendment mainly clarifies that Exhibit 99.1, a news release dated November 6, 2025, is incorporated by reference into two existing Form F-3 shelf registration statements.
Janus Henderson Group plc and its affiliated Janus Henderson Biotech Innovation Master Fund Ltd report substantial beneficial holdings in Bright Minds Biosciences Inc. The parent reporting person discloses ownership of 1,145,660 shares representing 16.3% of the outstanding common stock, while the fund reports 984,485 shares or 14.0%. Both reporting persons indicate shared voting and dispositive power for their respective holdings and 0 shares of sole voting or dispositive power.
The filing identifies the reporting entities as institutional investors (designations include IA, HC for the parent and IV for the fund), notes that certain subsidiaries act as registered investment advisers, and includes a power-of-attorney authorizing compliance filings.
Bright Minds Biosciences' Schedule 13G/A shows Sio Capital Management, LLC beneficially owns 512,338 common shares, representing 7.27% of the outstanding class based on 7,043,989 shares disclosed by the issuer. Sio reports shared voting and shared dispositive power and no sole voting or dispositive power. Sio is a Delaware registered investment adviser to affiliated funds that directly hold the reported shares. A footnote states Sio GP, LLC and Michael Castor may be deemed to have influence, though that beneficial ownership is expressly disclaimed. The filer certifies the holdings are held in the ordinary course of business and not to change control.